Intent to Sole Source for Sentinel 2.0 Bridge Contract to Harvard Pilgrim Health Care Inc.

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA CENTER FOR DRUG EVALUATION AND RESEARCH

Contract Value

Not provided

Codes & Classification
Solicitation Number

FDAINTENTTOSOLESOURCESENTINEL2

NAICS

-

Classification Code

B537

Additional Details
Set Aside

NONE

Place of Performance

Silver Spring, Maryland, UNITED STATES

SourceSAM
The Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a Special Notice indicating its intent to award a sole source bridge contract to Harvard Pilgrim Health Care Inc. This contract is designed to ensure the uninterrupted continuation of Sentinel 2.0 operations, a critical national system for post-market drug safety surveillance. The bridge contract will serve as a temporary measure to maintain current service levels and operational momentum until the competitive follow-on contract, Sentinel 3.0, is awarded. The scope of this procurement encompasses the ongoing operation and support of the Sentinel System, including the Active Post-market Risk Identification and Analysis (ARIA) System, Real-World Evidence (RWE) claims and EHR-linked data, and essential leadership and program management functions. The contract also covers Atlassian Access and activities necessary to maintain compliance with the Federal Information Security Modernization Act (FISMA). These services are vital to the FDA’s mission to monitor and evaluate the safety profiles of drugs available to American consumers, leveraging advanced epidemiological methods and electronic healthcare data. The period of performance for this bridge contract is structured as follows: - Base Period: March 29, 2026 – September 28, 2026 (six months) - Option Period 1: September 29, 2026 – March 28, 2027 (six months) - Option Period 2: March 29, 2027 – September 28, 2027 (six months) Harvard Pilgrim Health Care Inc. is the incumbent contractor and is uniquely positioned to provide these services without disruption, given its established expertise and operational knowledge of the Sentinel System. The FDA has determined that a sole source award is necessary to prevent a lapse in critical services and to ensure continuity until a competitively awarded, long-term contract is in place. The Sentinel System itself is a Congressionally mandated program, established under the FDA Amendments Act of 2007 (FDAAA 2007), which requires the FDA to collaborate with public, academic, and private entities to access and analyze disparate healthcare data sources. The system supports the FDA’s statutory requirements under section 505(o)(3)(D)(i) of the Federal Food, Drug, and Cosmetic Act and aligns with the 21st Century Cures Act, which emphasizes the use of Real-World Evidence (RWE) in post-approval studies. The Sentinel System’s infrastructure includes a national electronic ARIA system with data on at least 100 million individuals and a “Queryable–EHR” with at least 10 million lives, supporting the FDA’s Office of Surveillance and Epidemiology (OSE) in its mission. The place of performance for this contract is Silver Spring, Maryland. The procurement is classified under Product Service Code B537, with no set-aside restrictions. The contracting entity is the FDA Center for Drug Evaluation and Research. Interested parties who believe they can fulfill the requirements outlined in this notice are invited to submit written expressions of interest, including a clear demonstration of their capabilities, within 15 calendar days of the notice’s publication. All inquiries and responses must be directed via email to the primary contact, Howard S. Yablon ([email protected]), with a secondary contact available as Ian Weiss ([email protected]). The FDA will review all submissions to determine whether to pursue a competitive procurement process. However, this notice is not a request for competitive proposals, and the government reserves the right to proceed with the sole source award at its discretion. All proprietary information submitted will be handled in accordance with applicable government regulations. The government will not reimburse any costs associated with responding to this notice, and submissions will not be returned. For further details, the official notice can be accessed at: https://sam.gov/opp/d8cea16317f645e39f3c1cfa7d8a9351/view.